EGFR and non-small cell lung carcinoma: Recently, osimertinib demonstrated to dramatically improve disease-free survival (DFS) compared to placebo as adjuvant therapy in resected stage IB-IIIA EGFR-mutated NSCLC (ADAURA trial).15